Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma.

Trial Profile

Phase 2 Study of Safety and Efficacy of Nimotuzumab (TheraCIM) in Pediatric Patients With Recurrent Diffuse Intrinsic Pontine Glioma.

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Oct 2011

At a glance

  • Drugs Nimotuzumab (Primary)
  • Indications Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 31 Oct 2011 Interim results were reported at the 43rd Congress of the International Society of Paediatric Oncology conference (SIOP), according to a YM BioSciences media release.
    • 23 Sep 2011 Results to be reported in the second half of 2011, according to a YM BioSciences media release.
    • 04 Jul 2011 Actual end date (Dec 2010) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top